Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BET versus BBT in type 2 diabetes mellitus inadequately controlled on basal insulin glargine
2009-009500-39Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2009
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of exenatide, insulin lispro, insulin glargine and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to 30 weeks. Started Apr 2009; status: completed.
02
Drugs
exenatideinsulin lisproinsulin glarginemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-009500-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009500-39.